Mindfulness-Based Stress Reduction in Helping Participants with Metastatic Breast Cancer
- A diagnosis of metastatic breast cancer within the past 5 years and treated at Roswell Park Cancer Institute (RPCI)
- Ability to read and understand English
- Current distress score of 4+ on the National Comprehensive Cancer Network (NCCN) distress thermometer
- Access to an internet connection with own device (computer, tablet, smartphone, etc.)
- Patient not currently involved in an ongoing psychological intervention
- If taking prescribed medication for mood or anxiety disorder, dosage has been consistent for prior 3 months
- Unable to speak and understand English
- Prior or current experience with mindfulness-based practice
- Diagnosis of a psychotic disorder, bipolar disorder, substance abuse disorder, or reported suicidality
- Current involvement in any other psychological treatment (excluding medication) during study duration
- Currently being treated for another cancer diagnosis other than metastatic breast cancer
I. To develop a novel online mindfulness-based stress reduction (MBSR) treatment for distressed metastatic breast cancer patients in the hope of reaching patients otherwise unable to participate in traditional interventions due to high symptom burden.
II. Determine the impact of the intervention on both patient self-report and biological symptom measures.
OUTLINE: Participants are randomized to 1 of 2 arms.
INTERVENTION ARM: Participants receive online group sessions over 60 minutes for 6 weeks, including 15 minutes of practice on that session's topic and daily meditation or yoga for 45 minutes. At the conclusion of the study period participants participate in mindfulness meditation over 3 hours. Participants also receive a content manual and relaxation compact disc (CD).
CONTROL ARM: Participants randomized to the wait-list control condition complete the online intervention as in the intervention arm after the initial 6-week period has ended.
Trial Phase Phase NA
Trial Type Supportive care
Roswell Park Cancer Institute
- Primary ID I 50317
- Secondary IDs NCI-2018-00453
- Clinicaltrials.gov ID NCT03683147